{"id":8064,"date":"2023-03-02T20:50:16","date_gmt":"2023-03-02T19:50:16","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=8064"},"modified":"2023-03-02T20:54:55","modified_gmt":"2023-03-02T19:54:55","slug":"approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/","title":{"rendered":"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023)"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"8064\" class=\"elementor elementor-8064\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-50df2e2 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"50df2e2\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e880f51\" data-id=\"e880f51\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2497813 elementor-widget elementor-widget-text-editor\" data-id=\"2497813\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><em>En tant que pr\u00e9sidente et maman confront\u00e9e \u00e0 la maladie depuis plus de 30 ans, je comprends tr\u00e8s bien la d\u00e9ferlante de questions et d\u2019espoir que suscite l\u2019avanc\u00e9e de ce dossier pour cette mol\u00e9cule. Retarder l\u2019\u00e9volution de la maladie serait d\u00e9j\u00e0 un grand pas, d\u2019autant que d\u2019autres mol\u00e9cules seront s\u00fbrement disponibles dans les ann\u00e9es proches, d\u2019autres essais cliniques progressant bien.<\/em><br \/><em>Myriam Ra\u00ef a d\u00e9velopp\u00e9 les \u00e9tapes connues \u00e0 ce jour sur la suite du dossier. Confiance : la communaut\u00e9 Friedreich, m\u00e9decins, chercheurs, laboratoires et associations n\u2019ont qu\u2019un objectif : contrer l\u2019AF \u00ab Cure FA ! \u00bb.<\/em><br \/><em>Juliette Dieusaert, avec le CA AFAF<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a8b09c5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a8b09c5\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5a5d188\" data-id=\"5a5d188\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2ad0755 elementor-widget elementor-widget-text-editor\" data-id=\"2ad0755\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Ce 28 f\u00e9vrier 2023, la Food and Drug Administration (FDA) a approuv\u00e9 l&#8217;omaveloxolone (SKYCLARYS \u2122) pour les personnes atteintes d&#8217;ataxie de Friedreich (AF) \u00e2g\u00e9es de 16 ans ou plus aux Etats-Unis.<\/p><p>L&#8217;Omaveloxolone a pu am\u00e9liorer de mani\u00e8re significative la fonction neurologique (mesur\u00e9e \u00e0 l&#8217;aide de l&#8217;\u00e9chelle d&#8217;\u00e9valuation modifi\u00e9e de l&#8217;ataxie de Friedreich, mFARS) dans l&#8217;essai MOXIe, une \u00e9tude multinationale phase 2, d\u2019un an, en double aveugle contr\u00f4l\u00e9e par placebo.<br \/>L&#8217;\u00e9tude d&#8217;extension de 3 ans a montr\u00e9 un ralentissement de la progression de plus de 50 % par rapport \u00e0 un groupe de patients AF confront\u00e9s \u00e0 l\u2019\u00e9volution naturelle de la maladie.<br \/>L\u2019approbation de ce m\u00e9dicament repr\u00e9sente une premi\u00e8re \u00e9tape importante pour les personnes atteintes d\u2019AF.<\/p><p>Aux USA, selon le programme REACH communiqu\u00e9 par Reata pour l\u2019accessibilit\u00e9 aux Etats-Unis, le m\u00e9dicament sera disponible mensuellement dans une pharmacie de sp\u00e9cialit\u00e9 qui travaillera sur base de dossier entre le patient, son m\u00e9decin et son assurance. Plus d\u2019informations sur <a href=\"https:\/\/reatareach.com\" target=\"_blank\" rel=\"noopener\">https:\/\/reatareach.com<\/a>.<\/p><p>En Europe, Reata a d\u00e9pos\u00e9 la demande d&#8217;autorisation de mise sur le march\u00e9 (AMM) de SKYCLARYS\u2122 fin 2022 et l&#8217;Agence europ\u00e9enne des m\u00e9dicaments (EMA) l&#8217;examine actuellement.<br \/>Lors de la conf\u00e9rence de presse de Reata, dont vous pouvez \u00e9couter l\u2019int\u00e9gralit\u00e9 sur\u00a0<a href=\"https:\/\/events.q4inc.com\/attendee\/939887927?t=1677673027025\" target=\"_blank\" rel=\"noopener\"> https:\/\/events.q4inc.com\/attendee\/939887927?t=1677673027025<\/a>, il a \u00e9t\u00e9 communiqu\u00e9 que la compagnie pharmaceutique esp\u00e8re une disponibilit\u00e9 de SKYCLARYS\u2122\u00a0 en Europe en 2024 <strong>si le produit est approuv\u00e9 par l\u2019EMA<\/strong>. La compagnie serait en discussion pour un acc\u00e8s pr\u00e9coce \u00e0 cette date dans certains pays europ\u00e9ens, sans fournir plus de d\u00e9tails ce jour.<br \/>Il n\u2019est donc pas encore possible pour le moment de se procurer SKYCLARYS\u2122 en France mais bien s\u00fbr l\u2019objectif est que l\u2019acc\u00e8s soit \u00e9tendu partout et le plus vite possible.<\/p><p>Des essais p\u00e9diatriques sont en cours de planification avec l\u2019EMA donc en Europe, et seul l\u2019\u00e2ge d\u2019inclusion a \u00e9t\u00e9 communiqu\u00e9 par Reata lors de cette conf\u00e9rence du 28 f\u00e9vrier : 6-16 ans.<\/p><p>Selon la notice de SKYCLARYS\u2122, il pourra \u00eatre prescrit \u00e0 toute personne atteinte de l\u2019AF \u00e2g\u00e9e d\u2019au moins 16 ans. Plus d\u2019infos dans le document PDF disponible sur <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216718Orig1s000lbl.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216718Orig1s000lbl.pdf<\/a>.<\/p><p>Pour comprendre le mode d\u2019action de l\u2019omaveloxolone, voir cette vid\u00e9o de FARA, sous-titr\u00e9e en fran\u00e7ais : <a href=\"https:\/\/www.youtube.com\/watch?v=ShynFqFiHUk\" target=\"_blank\" rel=\"noopener\">https:\/\/www.youtube.com\/watch?v=ShynFqFiHUk<\/a><\/p><p>Myriam Rai, PhD<br \/>Director of Global Relations &amp; Initiatives<br \/>Friedreich&#8217;s Ataxia Research Alliance (FARA)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>En tant que pr\u00e9sidente et maman confront\u00e9e \u00e0 la maladie depuis plus de 30 ans, je comprends tr\u00e8s bien la d\u00e9ferlante de questions et d\u2019espoir que suscite l\u2019avanc\u00e9e de ce dossier pour cette mol\u00e9cule. Retarder l\u2019\u00e9volution de la maladie serait d\u00e9j\u00e0 un grand pas, d\u2019autant que d\u2019autres mol\u00e9cules seront s\u00fbrement disponibles dans les ann\u00e9es proches, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1656,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"on","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"off","ocean_gallery_id":[],"footnotes":""},"categories":[44,43],"tags":[],"class_list":["post-8064","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-generales","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023) - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"description\" content=\"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l&#039;AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C&#039;est un grand pas vers l&#039;acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d&#039;autres mol\u00e9cules.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023) - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l&#039;AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C&#039;est un grand pas vers l&#039;acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d&#039;autres mol\u00e9cules.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-02T19:50:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-02T19:54:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"467\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"afafadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"afafadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/\"},\"author\":{\"name\":\"afafadmin\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/5424e5cbe70a962cadb85c217d565d80\"},\"headline\":\"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023)\",\"datePublished\":\"2023-03-02T19:50:16+00:00\",\"dateModified\":\"2023-03-02T19:54:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/\"},\"wordCount\":564,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"articleSection\":[\"Actualit\u00e9s g\u00e9n\u00e9rales\",\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/\",\"name\":\"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023) - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"datePublished\":\"2023-03-02T19:50:16+00:00\",\"dateModified\":\"2023-03-02T19:54:55+00:00\",\"description\":\"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/08\\\/actualite-afaf.png\",\"width\":700,\"height\":467,\"caption\":\"actualit\u00e9s AFAF\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2023\\\/03\\\/02\\\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/5424e5cbe70a962cadb85c217d565d80\",\"name\":\"afafadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g\",\"caption\":\"afafadmin\"},\"sameAs\":[\"https:\\\/\\\/www.afaf.asso.fr\"],\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/afafadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023) - Association Fran\u00e7aise Ataxie de Friedreich","description":"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/","og_locale":"fr_FR","og_type":"article","og_title":"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023) - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.","og_url":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2023-03-02T19:50:16+00:00","article_modified_time":"2023-03-02T19:54:55+00:00","og_image":[{"width":700,"height":467,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","type":"image\/png"}],"author":"afafadmin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"afafadmin","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/"},"author":{"name":"afafadmin","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/5424e5cbe70a962cadb85c217d565d80"},"headline":"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023)","datePublished":"2023-03-02T19:50:16+00:00","dateModified":"2023-03-02T19:54:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/"},"wordCount":564,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","articleSection":["Actualit\u00e9s g\u00e9n\u00e9rales","Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/","url":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/","name":"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023) - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","datePublished":"2023-03-02T19:50:16+00:00","dateModified":"2023-03-02T19:54:55+00:00","description":"FDA, a annonc\u00e9 que l\u2019omaveloxolone avait re\u00e7u l\u2019approbation comme th\u00e9rapeutique dans l'AF. Cette d\u00e9cision \u00e9tait tr\u00e8s attendue de la communaut\u00e9 Friedreich mondiale. C'est un grand pas vers l'acc\u00e8s \u00e0 cette mol\u00e9cule dans le monde, et \u00e0 d'autres mol\u00e9cules.","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/08\/actualite-afaf.png","width":700,"height":467,"caption":"actualit\u00e9s AFAF"},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2023\/03\/02\/approbation-de-la-fda-pour-lomaveloxolone-complements-dinformations-2-mars-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"Approbation de la FDA pour l\u2019omaveloxolone\u00a0:\u00a0 compl\u00e9ments d\u2019informations (2 mars 2023)"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/5424e5cbe70a962cadb85c217d565d80","name":"afafadmin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ea32b6ce0855ebf5342005d33882edc00166b7b68b900e16bebd2ab9a7c3295?s=96&d=mm&r=g","caption":"afafadmin"},"sameAs":["https:\/\/www.afaf.asso.fr"],"url":"https:\/\/www.afaf.asso.fr\/author\/afafadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/8064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=8064"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/8064\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/1656"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=8064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=8064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=8064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}